All posts by medical

New Allergy Insights May Improve Diagnosis and Treatment – Technology Networks

Results from a study led by investigators at Massachusetts General Hospital may help to improve the diagnosis and treatment of allergies, pointing to a potential marker of these conditions and a new therapeutic strategy.

Nearly one third of the world's population suffers from allergies. These conditions are caused by certain antibodiescalled IgE antibodiesthat bind to allergens such as peanuts and trigger a reaction that releases an array of molecules that cause allergic symptoms, and in extreme cases, potentially life-threatening anaphylaxis.

Scientists have been perplexed by the fact that many individuals have circulating allergen-specific IgE antibodies without ever developing allergy symptoms. For example, about half of the people who have peanut-specific IgE antibodies (or test positive to a peanut skin prick test) do not have peanut allergies. In addition, some allergic individuals outgrow their symptoms yet still retain detectable levels of circulating allergen-specific IgE.

To look into these mysteries, Robert Anthony, PhD, of the Center for Immunology and Inflammatory Diseases, and his colleagues compared IgE from individuals with peanut allergies with IgE from individuals without any allergies. The analyses revealed an increase in a particular sugar residue called sialic acid on IgE from peanut allergic individuals.

The researchers also found that adding sialic acid to IgE enhanced allergic reactions triggered by IgE in animal models, while removing sialic acid from IgE dampened these reactions and reduced anaphylaxis.

"Our results indicate that quantifying sialic acid on IgE may serve as a marker for more accurate diagnoses of allergic disease, and that removal of sialic acid from IgE is a novel strategy for treating affected patients," said Dr. Anthony.

Additional research on the mechanisms behind sialic acid's effects on IgE activity could provide additional insights into allergies and their causes. The team is currently planning studies to determine how removing sialic acid from IgE attenuates allergy, and develop strategies to exploit this therapeutically.

Reference:Shade, K. C., Conroy, M. E., Washburn, N., Kitaoka, M., Huynh, D. J., Laprise, E., . . . Anthony, R. M. (2020). Sialylation of immunoglobulin E is a determinant of allergic pathogenicity. Nature. doi:10.1038/s41586-020-2311-z

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read more from the original source:
New Allergy Insights May Improve Diagnosis and Treatment - Technology Networks

Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the Digital EAACI Annual Congress 2020 – GlobeNewswire

REDWOOD CITY, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the Company) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced the acceptance of two oral abstract presentations at the upcoming European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress being held virtually from June 6 to 8, 2020.

The following virtual oral abstract presentations will be available starting on June 6, 2020.

Following the presentations, the slides will be available on the Allakos website.

AboutAllakos

Allakos is a late-stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Companys lead antibody, antolimab (AK002), is being evaluated in a Phase 3 study in eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) and a Phase 2/3 study in eosinophilic esophagitis (EoE). Antolimab targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. Antolimab has been tested in multiple clinical studies, in which antolimab eliminated blood and tissue eosinophils, inhibited mast cells and improved disease symptoms in patients with eosinophilic gastritis and/or eosinophilic duodenitis, eosinophilic esophagitis, mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria and indolent systemic mastocytosis. For more information, please visit the Company's website at http://www.allakos.com.

Source: Allakos Inc.

Read the original here:
Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the Digital EAACI Annual Congress 2020 - GlobeNewswire

Vividion and Roche Partner on Research Pact Worth "Several Billion Dollars" – BioSpace

San Diego-based Vividion Therapeutics has entered into a collaboration deal with Roche. The companies will leverage Vividions proteomics screening platform and small molecule library to target novel E3 ligases in addition to a variety of oncology and immunology therapy targets.

When proteins are no longer needed or become damaged, they are degraded by proteasomes. E3 ligases are a class of proteins whose job it is to direct target proteins to the proteasome for degradation. Drugs that interact with E3 ligases have the potential for treatments for a broad range of therapies.

Under the terms of the deal, Roche is paying Vividion $135 million in cash up front. Vividion is eligible for several billion dollars in preclinical, development and commercial milestones in addition to royalties on sales of products that might come out of the partnership.

Roche has the exclusive right to license compounds that come out of the collaboration at different stages of development. Vividion is responsible for early drug discovery and preclinical activities for chosen programs. For a subset of the programs, Vividion holds the right to run clinical development up to proof-of-concept with an option to share development costs and split U.S. profits and losses with Roche.

We are thrilled to partner with Roche, marking the second major collaboration for Vividion focused on developing small molecule drugs against promising, untapped therapeutic targets, said Diego Miralles, chief executive officer of Vividion. This collaboration with Roche will further expand a new pillar of our pipeline focused on leveraging distinct E3 ligases to bring cutting-edge treatments to patients in need.

A year ago, in April 2019, Vividion announced an oversubscribed Series B financing worth $82 million. The round was led by Nextech Invest with participation from new investors BVF Partners, Casdin Capital, Mubadala Ventures, Trinitas Capital, Mirae Asset Capital, Altitude Life Science Ventures, and Alexandria Venture Investments. Existing investors ARCH Venture Partners, Versant Ventures, Cardinal Partners and Celgene Corporation also participated.

The companys approach is based on the work of Benjamin Cravatt at The Scripps Research Institute. It allows for screening of small molecules against every protein in native biological systems.

A year before that, in March 2018, Vividion inked a strategic research collaboration with Celgene Corporation, now part of Bristol Myers Squibb. The multi-year deal focused on identifying and developing unique small molecules against oncology, inflammatory and neurodegenerative indications.

Under that deal, Celgene paid Vividion $101 million up front that included an equity investment from Celgene. The initial length of the collaboration was four years, with Celgene able to extend for another two years for an additional fee.

Of the deal with Roche, Fred Aslan, Vividions president and chief business officer, stated, Our proprietary platform has demonstrated the ability to identify molecules that can drug challenging protein classes, such as transcription factors, adaptor proteins, and E3 ligases. We look forward to discovering new therapies with Roche while simultaneously advancing our wholly owned pipeline.

On Roches part, James Sabry, Global Head of Roche Pharma Partnering, noted, Partnering is a cornerstone of Roches research strategy to transform novel ideas into medicines. We are excited about Vividions approach to small molecule discovery and are looking forward to working with their team to discover potential new medicines for patients with cancer and immunological diseases.

Go here to see the original:
Vividion and Roche Partner on Research Pact Worth "Several Billion Dollars" - BioSpace

Roche enters $135m drug discovery deal with Vividion Therapeutics – Pharmaceutical Technology

]]> The companies discover and develop small molecules for various therapeutic targets. Credit: Steve Buissinne from Pixabay.

Roche has signed an exclusive worldwide option and licence agreement with US-based biotechnology firm Vividion Therapeutics to discover and develop small molecules for various therapeutic targets.

Under the alliance, Vividion Therapeutics will use its proteomics screening platform and small molecule library for E3 Ligases, as well as certain oncology and immunology targets.

E3 ligases are a class of proteins that direct target proteins to the proteasome for degradation. Small molecules directed to E3 ligases could possess the potential for a variety of therapeutic applications.

Roche holds the exclusive right to licence compounds resulting from the collaboration at different development stages.

Our parent business intelligence company

Vividion Therapeutics president and chief business officer Dr Fred Aslan said: Our proprietary platform has demonstrated the ability to identify molecules that can drug challenging protein classes, such as transcription factors, adaptor proteins and E3 ligases.

We look forward to discovering new therapies with Roche while simultaneously advancing our wholly-owned pipeline.

Under the agreement, Vividion will carry out early drug discovery and pre-clinical development for select programmes.

The company holds the right to perform clinical development up to proof-of-concept for a subset of programmes, with an option to share development costs and split profits and losses in the US with Roche.

Roche Pharma Partnering global head James Sabry said: We are excited about Vividions approach to small molecule discovery and are looking forward to working with their team to discover potential new medicines for patients with cancer and immunological diseases.

Roche will pay $135m in an upfront payment to Vividion, which is also eligible for several billion dollars in preclinical, development and commercial milestones, as well as sales royalties.

Last month, Roche entered a collaboration and licence agreement with Arrakis Therapeutics to discover RNA-targeted small molecule (rSM) drugs against various targets.

Go here to see the original:
Roche enters $135m drug discovery deal with Vividion Therapeutics - Pharmaceutical Technology

Danbury resident earns SURF award to pursue research with faculty mentors – HamletHub

Two Western Connecticut State University students will gain invaluable hands-on experience in studies contributing to understanding of human physiology and climate change impact on species survival with support from the Summer Undergraduate Research Fellowship (SURF) program offered by the WCSU Department of Biological and Environmental Sciences.

James Hannon, of Danbury, and Emily Hoegler, of Bethel, have received the departments 2020 SURF awards to pursue research studies coordinated by mentors from the universitys biology faculty. Hannons research, mentored by Associate Professor of Biological and Environmental Sciences Dr. Michelle Monette, will explore the impact that environmental stress caused by climate change has produced in Atlantic killifish, an important source of prey for many species found in coastal estuaries. Hoegler will continue work with her mentor, Associate Professor of Biological and Environmental Sciences Dr. Joshua Cordeira, to study how the expression or suppression of dopamine, a chemical whose release commonly increases during exercise, affects food intake behavior and propensity to gain weight.

Hannon and Hoegler competed successfully in a process open to applicants from WCSU and other colleges for the two SURF positions awarded annually by a department faculty review committee. The continuing limitations on campus access during the Covid-19 crisis have required the SURF committee to defer the timeframe for realization of their projects to summer 2021, when they will complete their field and laboratory studies over an eight- to 10-week period, submit a technical paper and present findings at a scientific forum. Each student will receive a $4,000 stipend upon successful completion of the program.

SURF programs are offered at universities nationwide with the goal of stimulating interest in research opportunities and careers in the STEM disciplines. Monette observed the SURF program in biology at WCSU provides an intensive research experience that also affords the chance to consider future career objectives. This program is integral to our departments ability to provide motivated undergraduates with the opportunity to gain skills and confidence in laboratory and field-based research, she said.

Hannon, a biology major with a concentration in environmental science, gained an introduction to study of biodiversity and common species in brackish waters during field work tracking diamond-back terrapins in southern Connecticut under the guidance of Professor of Biological and Environmental Studies Dr. Theodora Pinou. His studies with Monette this winter provided the scientific foundations to investigate how animals use physiological attributes to adapt to their environment, and how their survival is threatened when these mechanisms are overwhelmed by rapid environmental change.

As environmental temperature rises, oxygen becomes less soluble in water, which requires gilled animals to pass more water over their gills to maintain homeostatic oxygen levels, Hannon said. This presents a problem for fish, particularly those in marine and estuarine waters, because as water intake increases, so does the intake of salt. Our goal is to determine the impact of elevated water temperatures on salinity tolerance by analyzing patterns in gene expression and developing genetic biomarkers that will further the scientific communitys understanding of multiple stressors on estuarine fish.

During the present campus closure, Hannon has prepared for his research work through a thorough investigation of the biological literature on his subject, and he plans to work with Monette in an independent study course during the fall semester. He also recently earned a Connecticut Sea Grant Undergraduate Research Fellowship with an award of $5,000 supporting his summer 2021 project. The Sea Grant fellowship is awarded to broaden participation of underrepresented and underserved students in marine and coastal professions through research, training and mentorship opportunities.

These fellowships will provide me with real-world experience in field collection techniques, fish husbandry, laboratory procedures, genetic data analysis and scientific communication, he said. These are invaluable lessons, providing the knowledge that I hope to carry on to graduate school and a career in an agency or company focused on conservation.

Hannon credited his progress toward achievement of these goals to his wife, Sam, and the passionate and incredibly knowledgeable members of the WCSU biology faculty including Monette, Pinou, and Associate Professors Dr. Rachel Prunier and Dr. Edwin Wong. As a father of two young girls, I feel it is my absolute duty to do what I can to protect and repair local ecosystems, he said. Retention of the biodiversity we see in plants, animals and even bacteria is critically important for our planet to continue to support human life for future generations.

Hoegler, a biology major specializing in human exercise physiology, has worked in Cordeiras laboratory for the past year as a student research assistant investigating the effectiveness of exercise in altering food intake behavior and preventing weight gain. Inspired by a hypothesis posed by another student lab assistant, Katie DuFrirsz, that changes in dopamine levels during exercise may alter motivation to consume high-fat foods, Cordeiras research team has found further promising findings in the scientific literature on which Hoegler aims to build in her fellowship project.

A lot of previous work has established that exercise increases dopamine expression in the human body, she explained. I want to look at what that means for appetite and high-fat food consumption, which has been strongly implicated in the spread of obesity. I have always been interested in health and wellness, and this topic is of great significance now with the growing obesity epidemic and all its associated health issues.

Hoegler pursued an independent study course with Cordeira during the past semester that demanded extensive research on the various mechanisms of human physiology that may contribute to the effectiveness of exercise in decreasing appetite. Her fellowship project will use experimental and control groups of mice to establish a baseline for food consumption with or without exercise, based on whether or not the mice have access to an open running wheel. She will then inhibit dopamine reception in the experimental group to determine its effect on motivation to run and subsequently to consume food.

If inhibiting D2 dopamine receptors decreases their motivation to run, and therefore prevents the mice from obtaining the rewards of running through decreased food intake and subsequent weight loss, the study would point to a relationship between higher dopamine expression and weight loss induced by exercise, she noted. This could contribute to the field of exercise physiology, because it would help to determine the ways in which exercise decreases appetite and prevents weight gain and to find ways to make weight loss easier and more efficient.

Hoegler plans to pursue research on human physiology in graduate school after completing her WCSU major in biology and minor in philosophy in 2021. She described Cordeira as an amazing mentor whose laboratory has offered valuable research opportunities that have continued online through Webex meetings during the current pandemic, and whose guidance offers support in preparing for graduate studies. She also credited Assistant Professor Dr. Kristin Giamanco for her support in pursuing the SURF grant and for her academic and career guidance.

For more information, contact Monette at This email address is being protected from spambots. You need JavaScript enabled to view it. or Sherri Hill of the Office of University Relations at This email address is being protected from spambots. You need JavaScript enabled to view it. . For background on the SURF program at WCSU, visit http://www.wcsu.edu/biology/surf/

See the article here:
Danbury resident earns SURF award to pursue research with faculty mentors - HamletHub

UBC scientist identifies a gene that controls thinness – UBC Faculty of Medicine – UBC Faculty of Medicine

Why can some people eat as much as they want, and still stay thin?

In a study published today in the journal Cell, Life Sciences Institute Director Dr. Josef Penninger and a team of international colleagues report their discovery that a gene called ALK (Anaplastic Lymphoma Kinase) plays a role in resisting weight gain.

We all know these people, who can eat whatever they want, they dont exercise, but they just dont gain weight. They make up around one per cent of the population, says senior author Penninger, professor in the Faculty of Medicines department of medical genetics and a Canada 150 research chair.

Dr. Josef Penninger

We wanted to understand why, adds Penninger. Most researchers study obesity and the genetics of obesity. We just turned it around and studied thinness, thereby starting a new field of research.

Using biobank data from Estonia, Penningers team, including researchers from Switzerland, Austria, and Australia, compared the genetic makeup and clinical profiles of 47,102 healthy thin, and normal-weight individuals aged 20-44. Among the genetic variations the team discovered in the thin group was a mutation in the ALK gene.

ALKs role in human physiology has been largely unclear. The gene is known to mutate frequently in several types of cancer, and has been identified as a driver of tumour development.

Our work reveals that ALK acts in the brain, where it regulates metabolism by integrating and controlling energy expenditure, says Michael Orthofer, the studys lead author and a postdoctoral fellow at the Institute of Molecular Biology in Vienna.

When Penningers team deleted the ALK gene in flies and mice, both were resistant to diet-induced obesity. Despite consuming the same diet and having the same activity level, mice without ALK weighed less and had less body fat.

As ALK is highly expressed in the brain, its potential role in weight gain resistance make it an attractive mark for scientists developing therapeutics for obesity.

The team will next focus on understanding how neurons that express ALK regulate the brain at a molecular level, and determining how ALK balances metabolism to promote thinness. Validating the results in additional, more diverse human population studies will also be important.

Its possible that we could reduce ALK function to see if we did stay skinny, says Penninger. ALK inhibitors are used in cancer treatments already, so we know that ALK can be targeted therapeutically.

The study was supported by the Estonian Research Council, the European Union Horizon 2020 fund, and European Regional Development Fund, the von Zastrow Foundation, and the Canada 150 Research Chairs Program.

Read more from the original source:
UBC scientist identifies a gene that controls thinness - UBC Faculty of Medicine - UBC Faculty of Medicine

Nautilus Biotechnology Raises $76 Million in Series B Funding to Be the First to Quantify the Human Proteome – Business Wire

SAN CARLOS, Calif & SEATTLE--(BUSINESS WIRE)--Nautilus Biotechnology, a company pioneering a high-throughput, low-cost platform for analyzing and quantifying the human proteome, today announced it has raised $76 million in an oversubscribed Series B offering that closed on Monday, May 18, 2020. Nautilus total funding now exceeds $100 million. The Nautilus platform will deliver single-molecule sensitivity more quickly, more completely, and less expensively than is possible with existing technologies. This deeper, richer understanding of proteins will enable a dramatic acceleration of basic science research, significantly improve the success rate of therapeutic development, and speed the adoption of personalized and predictive medicine.

The funding round was led by Vulcan Capital, the multi-billion-dollar investment arm of Vulcan Inc., the company founded by Microsoft co-founder and philanthropist Paul G. Allen. In addition to Vulcan, Perceptive Advisors, Bezos Expeditions, and Defy Partners were new investors in the Series B offering. Previous investors AME Cloud Ventures, Andreessen Horowitz, Bolt, and Madrona Venture Group also participated in the round. The capital will be used to accelerate development of Nautilus proprietary proteomics platform and the expansion of scientific and engineering staff across a variety of levels and disciplines.

Nautilus was co-founded in 2016 by Sujal Patel, founder and CEO of Isilon Systems, a publicly-traded company that sold to EMC in 2010 for $2.6B, and Parag Mallick, PhD, Associate Professor of Radiology at Stanford University and a member of BioX, Stanford's pioneering interdisciplinary biosciences institute, and the Canary Center for Cancer Early Detection. The leadership team combines its entrepreneurial and research backgrounds to solve the challenge of more easily and completely quantifying the proteins that drive every aspect of human physiology. That limitation has impeded scientific and pharmaceutical R&D and Nautilus platform will enable a more comprehensive understanding of cellular and organismic biology.

Existing proteomics technologies are slow, expensive, incomplete, and lack the sensitivity to deliver deep and meaningful insight into biological processes, said Nautilus co-founder and CEO, Sujal Patel. Bringing together Parags breakthrough science with my deep understanding of large-scale IT has enabled us to approach the problem in a fundamentally new, more holistic way. Our value derives from a unique, interdisciplinary combination of biochemistry, computer science, and substantial business experience.

The potential of proteomics has not been fully realized because of the limitations of current analysis methods, said Lee Hartwell, PhD, President and Director Emeritus of the Fred Hutchinson Cancer Research Center, 2001 co-recipient of the Nobel Prize in Physiology and Medicine, and member of Nautilus Scientific Advisory Board. A greater resolution of the proteome will make it possible for the entire scientific and pharma R&D communities to undertake a wider range of high-value scientific inquiries, thereby accelerating both their research and the benefits that can accrue to human health.

Advancing scientific research and technology is at our core, said Stuart Nagae, Director of Venture Capital at Vulcan Capital. With over a decade of experience investing in biotech and proteomics innovation, we believe that a reimagining of proteomics is long overdue. Nautilus has put together a special team with the vision, creativity, and experience to achieve that breakthrough, and execute on their vision.

ABOUT NAUTILUS BIOTECHNOLOGY

Based in San Carlos, CA and Seattle, WA, Nautilus is a biotechnology company whose proteomics platform will deliver superior sensitivity far more quickly, more completely, and less expensively than is currently possible. By breaking through the limitations of existing technologies, and effectively democratizing proteomics, Nautilus will enable a dramatic acceleration of basic science research, significantly improve the success rate of therapeutic development, and usher in a new era of personalized and predictive medicine. Find Nautilus online: http://www.nautilus.bio

ABOUT VULCAN CAPITAL

Vulcan Capital is the multi-billion-dollar investment arm of Vulcan Inc., the company founded by Microsoft co-founder and philanthropist Paul G. Allen. Vulcan Capital focuses on generating long-term value appreciation across a portfolio, which spans diverse industry sectors and investment asset classes, ranging from early-stage venture investments to public equity value investing, leveraged buyouts, acquisitions, special situations and fixed income. Vulcan Capital was formed in 2003 and is headquartered in Seattle with additional offices in Palo Alto and Singapore.

See the article here:
Nautilus Biotechnology Raises $76 Million in Series B Funding to Be the First to Quantify the Human Proteome - Business Wire

MPBSE 2020: Check the 12th Board Time Table And Other Details – Republic World – Republic World

Madhya Pradesh Board class 12th time table has been declaredon its official website. Check the official announcement from this link - http://mpbse.nic.in/The new dates for Madhya Pradesh Board class 12thexams havebeen declared from June 8 toJune 16, 2020.MP Board Class 12th exams have a revised examination pattern and passing marks now.Theboard exam was postponed due to COVID-19, but now after four phases of lockdown, India is slowly getting used to the new normal and is slowly restarting life as before.

image courtesy: MPBSE official website

ALSO READ|Karnataka SSLC Exam Time Table And Other Schedule Details That You Need To Know

image courtesy: MPBSE official website

image courtesy: MPBSE official website

For those who can't view the image properly, check out the table belowfor the morning shift.

June 9, 2020 - Higher Mathematics

June 10, 2020- Book Keeping and Accountancy

June 11, 2020 - Biology

June 12, 2020 - Business Economics

June 13, 2020 - Political Science

June 15, 2020 - Chemistry

ALSO READ|AP SSC Exam 2020 Time Table Out, 10th Board Exams Starting From July 10 | See Details

For the evening shift-

June 9, 2020 - Geography

June 10, 2020- Crop Production and Horticulture / First Paper for Vocational Course

June 11, 2020 -Economics

June 12, 2020 -Animal Husbandry, Milk Trade, Poultry and Fisheries

June 13, 2020 - Anatomy, Physiology and Health, Still Life and Design, Second Paper for Vocational Course

June 15, 2020 - Science Elements, History of Indian Art, Third Paper for Vocational Course

ALSO READ|Kerala SSLC Exam Time Table 2020: SSLC And Plus Two Exams To Be Held From May 26, 2020

ALSO READ|Bihar Board 10th Result: Here's Everything You Need To Know

Link:
MPBSE 2020: Check the 12th Board Time Table And Other Details - Republic World - Republic World

Hiking, Social Distancing and Human Behavior in the Summer of COVID-19 – Seven Days

The Jerusalem Trail in Starksboro ascends from a dirt road, climbing for 2.4 miles through hardwood forest and an expanse of maples, connected by a cat's cradle of sap lines, until it intersects with the Long Trail two miles north of the summit of Mount Ellen. A wooden post announcing the trailhead bears a laminated sign that reads, "TRAIL CLOSED."

Cecilia Elwert, 67, is one of the Green Mountain Club's roughly 1,000 volunteers. She has been maintaining the Jerusalem Trail digging drainage channels, clearing fallen branches, lopping unruly boughs for more than a decade. Her work has gotten off to an unusually late start; typically, she might begin in mid-April, when the snow has mostly melted at lower elevations. But this spring, the GMC asked its volunteers to keep off the trails until Gov. Phil Scott amended the stay-at-home order to allow outdoor crews to return to work.

On a chilly Thursday morning in mid-May, Elwert had resolved to investigate the blowdown situation on the ridge. She parked her Subaru Outback along the shoulder of the dirt road with the "GMC Volunteer" sign clearly visible in her windshield, hoping to disabuse would-be hikers of the notion that the trail was open to the public. Elwert carried a long-handled rake and a 20-pound backpack filled with various sharp implements for pruning and sawing; I followed at a six-foot distance, schlepping her garden hoe.

As we made our way up the trail, Elwert paused every 10 or 15 yards to clear debris from water bars, man-made earthen gutters that carry runoff away from the trail. "I get to come out here and play Army Corps of Engineers," she told me, her blue eyes crinkling in a smile concealed beneath her face mask. "It's fucking great."

In one of the canals, she found a forked, six-inch-long twig that had collected a novel-thick sheath of dead leaves between its prongs. "Can you believe it? Water made this!" she marveled.

Occasionally, Elwert came upon a stone in the middle of the path and nudged it with her foot to see if it was loose. "I could move that," she mused at one point, jiggling a bowling-ball-size rock beneath her KEEN boot, "or I could teach someone a goddamn lesson about paying attention."

Elwert struggles with what she perceives as the oblivious consumption of nature by she's not shy about naming culprits the Instagram generation, the people who use the outdoors as a backdrop to evince their coolness. Lately, a pandemic-induced surge in hikers has compounded her frustration, and she fears that their uncontrolled presence will ruin the summer for everyone.

"People are so ravenous to be out on the trails right now," Elwert said. "And when they post photos of themselves standing triumphantly on a summit, other people see it and think it looks authoritative like, 'Hey, the mountain is open!'"

Her concerns aren't unfounded: Across the country, the restless quarantined masses have been swarming green spaces, prompting officials and conservation groups to impose restrictions in the interest of human and environmental health.

In New Hampshire, the Appalachian Mountain Club closed all its huts in the White Mountains for the summer, citing concerns about excessive crowding. Earlier this month, the U.S. Forest Service in Vermont closed backcountry campsites throughout the Green Mountain National Forest, a 400,000-acre swath of land, to preempt a run on the wilderness and reduce the risk of transmission in structures too remote to be consistently sanitized.

The Long Trail closed in late March in accordance with public health recommendations, even though the trail was already nominally "closed" for mud season. But Keegan Tierney, director of field programs for the Green Mountain Club, acknowledges that enforcing trail closures is a logistical impossibility.

Over the past few weekends, he said, some hiking spots along the Long Trail particularly the Burrows Trail in Huntington, one of the shorter routes to the summit of Camel's Hump have experienced the same number of visitors as peak foliage season. (A solar message board on the road to the Burrows Trail parking lot, flashing the words "Trail Closed," has not had the intended effect.)

Since the beginning of May, GMC volunteers like Elwert have been preparing the 272-mile Long Trail, as well as the 166 miles of side trails under the GMC's stewardship, for their official reopening on Memorial Day weekend. However, Tierney said that Long Trail facilities, including shelters and composting toilets, would likely remain closed for several more weeks, largely because of the challenge of ensuring proper sanitization in the backcountry.

Overnight tenting will still be permitted, provided that campers respect ecologically sensitive areas and social-distancing etiquette, and the Department of Forests, Parks and Recreation is advising hikers to wear cloth masks whenever other people are present a small price to pay for public health. "We're worried about staff and volunteer health, particularly for people who work near popular summits and backcountry ponds," said Tierney. "We don't want hikers to cluster at those sites."

In a normal spring, the GMC hires a seasonal crew of about 40 staffers. Most of them are in their twenties, noted Tierney, with the nomadish rsums of people who organize their lives around being outside. When they're not clearing trails and patrolling ridgelines, the crew shares a bunkhouse in Waterbury Center, where sickness could easily spread: "If one person got sick, everyone would get sick," he said.

This year, Tierney plans to employ just 10 staffers. They'll target the most popular trails and summits including Mount Mansfield and Camel's Hump, both of which receive more than 50,000 visitors each summer and Stratton Pond in southern Vermont, the largest body of water on the Long Trail. But he emphasized that the trail crew doesn't have the capacity to act as social-distancing police.

"We're going to focus on educating people about being responsible and considerate of other hikers, and maybe ask them to avoid taking a two-hour lunch break on the summit so that other people can enjoy it," Tierney said. People should treat this summer as an opportunity to expand their hiking repertoires, he added: "If the Burrows Trail parking lot is full, you can drive a short distance and be at the Beane Trail, or go to the Jerusalem Trail in Starksboro."

Pandemic-related hiring freezes have also stalled the reopening of the state's campgrounds, which were closed to overnight visitors by the same order that shuttered hotels, inns and Airbnbs. (The parks have remained open for day use.) When Scott cleared hospitality businesses to resume operations, starting on May 22, state parks began accepting campground reservations for June 15 or later.

But that date, as it turned out, was too optimistic. Campgrounds require a significant amount of preparation in a normal season, the labor of some 400 temporary employees to accommodate visitors. Until last week, Michael Snyder, commissioner of the state Department of Forests, Parks and Recreation, couldn't hire any seasonal workers, and the opening date had to be postponed, forcing the state to issue some $320,000 in reservation refund vouchers. Snyder and his staff are now working to get campgrounds up and running by June 26.

"There's an enormous amount of infrastructure that has to get opened up every year," said Snyder. "And in the time of a pandemic, we have to completely change the way we do things."

His department recently applied for a $2 million loan from the federal Coronavirus Aid, Relief and Economic Security Act to subsidize the cost of hand sanitizer and protective gear for employees. This season, Snyder said, cabins and cottages will remain closed, but lean-tos, RV hookups and tent sites will be available, sans picnic tables. Campgrounds won't offer any bike or boat rentals, and snack bars and gift shops will stay dark. As a precaution, the state is advising people to wear masks around the park, except when swimming, eating and hanging out at their campsites.

"We're trying to figure out how we can limit campground density, how we can sanitize cabins and sites between families, and how we do all of that while making sure that visitors from out of state have self-quarantined for 14 days," Snyder said. "There's no scenario in which we don't operate at a loss."

That prediction presents a rather depressing irony: If Vermont's summer looks anything like this spring, parks and trails will be teeming with people, some of whom might have contributed to the state's dwindling coffers in exchange for the privilege of recreating on public lands.

Snyder estimates that, each year, Vermont's state campgrounds take in $7 million in direct park sales reservation fees, firewood and travel-size tubes of toothpaste from the commissary. Overnight campers, half of whom come from outside Vermont, spend roughly $90 million at local businesses in the surrounding areas. But given the pandemic's impact on restaurants and retail not to mention the unemployment rate, currently at its highest since the Great Depression it's unclear how much disposable income people will have to spend this summer, or where they'll actually be able to spend it. In other words, the economic power of the state's outdoor recreation infrastructure might not be so multiplicative this year.

Elwert, the GMC volunteer, thinks that all these uncertain roads ultimately lead us back to nature. "Hiking is free," she said. "And people don't think of nature as a place where you can transmit disease."

In a pandemic world, the woods feel like the last pure place, a respite from the sensory sameness of life under quarantine. But in Vermont, the general public's experience of nature as a pristine refuge is, in fact, the product of massive amounts of human labor labor that often goes unseen, even in normal times.

Now, out of an abundance of caution, Elwert has been avoiding the trails on the weekends, when she would be more likely to encounter large groups of people. Sometimes, she said, she leaves little traces of her handiwork behind an overturned rock, a cleanly sawed-off tree limb as a signal to passersby that someone else cleared the way for them.

More here:
Hiking, Social Distancing and Human Behavior in the Summer of COVID-19 - Seven Days

New mathematical model to study the behavior of the human heart – News-Medical.Net

Having now reached its third year, Project "iHEART" of Politecnico di Milano, winner of an ERC Advanced Grant of euro 2,350,000, has set itself the ambitious goal of creating a complete mathematical model to study the behavior of the human heart and of its pathologies, a sort of "virtual microscope."

This integrates all cardiac function processes, namely electrical impulse propagation, cellular activation, contraction and myocardial relaxation during the systolic and diastolic phase, blood fluid dynamics in both ventricles and atria, and opening-closure dynamics of the four cardiac valves.

Research carried out to date has already allowed to initiate operations of certain subproblems, which are attracting considerable interest in the medical community. Hence, from feasibility studies, focus has shifted to early field tests, in which mathematicians and doctors cooperate to optimise these new tools in the framework of delicate surgical procedures intended to solve certain very important cardiac conditions.

Some examples are given below.

Models developed by project iHeart have led to the production of quantitative indications on factors that contribute to trigger and maintain arrhythmias, such as ventricular tachycardia. Traditional surgical methods consist in performing transcatheter ablations, which allow, via radio frequencies, to deactivate the abnormal areas causing the arrhythmia.

In partnership with the Arrhythmology Unit and with the Cardiac Electrophysiology Unit of the IRCCS [scientific institute for hospitalisation and care] San Raffaele Hospital, Milan, researchers verified how cardiac mathematics can underpin and consolidate electrophysiological study in the localisation of intervention areas on the heart wall.

Increasingly rapid algorithms, which will allow to perform this type of analysis in real time, thus significantly speeding up the decisional process related to surgery, have also reached an advanced phase of development.

A model is currently being developed in partnership with the Sacco Hospital, Milan, to provide precise indications for the heart surgeon on how to perform myectomy (removal) of a portion of the interventricular septum using a very low cost, non-invasive analysis.

This treatment is the one that is most widely used to treat hypertrophic obstructive cardiomyopathy, which consists in a septal thickening which makes hard to eject blood from the left ventricle into the ascending aorta.

The mathematical simulation is inserted into the preoperative phase and was considered by medical doctors as an effective guiding tool for this surgical operation.

An additional computational tool has been developed in partnership with the Cardiology and Radiology Departments of S. Maria del Carmine Hospital, Rovereto (TN), to improve cardiac resynchronisation therapy (CRT), which consists in implanting a device capable of restoring correct synchronisation of the heart contraction impaired either by conduction disorders or by the presence of scars.

To this end, cardiologists have to map the left ventricle to detect its electrical activity by inserting a catheter-electrode into the blood vessels.

The currently validated mathematical instrument will allow to considerably reduce the mapping duration and, thus, the patient exposure to invasive treatment, besides guiding catheter placement in the most curative position for the patient presenting heart failure.

As shown by these examples, iHEART has opened new horizons between mathematics and translational medicine, and has established coordinated and systematic action between Universities and hospitals, creating a new professional figure at the interface between mathematics, bioengineering, medicine and data science.

As a result of all the new clinical partnerships, and the integrated activity of our young researchers (PhD students and post-doctorate graduates) with that of hospital-based researchers, we shall pave the way for a new discipline, namely Computational Medicine."

Alfio Quarteroni, Professor and Project Manager, Politecnico di Milano

Alfio Quarteroni Professor, Politecnico di Milano, Milan, Italy and Professor Emeritus, EPFL, Lausanne, Switzerland acknowledged as one of the most multi-faceted mathematicians in the world, famous for applying mathematics to the most diverse fields: aerospace industry, environmental pollution, impact of earthquakes on civilian buildings, urban planning, medicine, and even competitive sports.

Particularly, he participated in producing the Solar Impulse aircraft, and directed the team of researchers who developed the mathematical model for Alinghi, the Swiss yacht twice winner of the prestigious America's Cup, the Sailing Cup, for two consecutive editions of the race, in 2003 and 2007.

Continue reading here:
New mathematical model to study the behavior of the human heart - News-Medical.Net